AGC Biologics Expands Capacity at Denmark Facility
AGC Biologics, a Bothell, Washington-headquartered contract development and manufacturing organization of biologics, is increasing manufacturing capacity at its Copenhagen, Denmark facility.
The Copenhagen facility will add a single-use bioreactor “6Pack” suite, consisting of six 2,000-liter production bioreactors and a 2,000-liter seed train. The addition of this proprietary bioreactor configuration is designed to enable more flexible and customized cGMP production capabilities by offering scales from 2,000 liters to 12,000 liters within a single run. The six bioreactors will be run in single unit operations or in groups and simultaneously, sequentially or staggered to meet specific production needs.
The expansion also includes additional capabilities for harvesting, purification, buffer, and media production that will support the processing of different therapeutic proteins, including high antibody titer processes. The new suites are scheduled to be on line in November 2018 are expected to support the manufacturing of several commercial products.
Source: AGC Biologics